Subskrypcja JoVE jest wymagana do oglądania tego materiału. Zaloguj się lub rozpocznij bezpłatny okres próbny.

Artykuł badawczy

S100P as a Shared Biomarker in Inflammatory Bowel Disease, Colorectal Cancer, and Pancreatic Adenocarcinoma: An Integrated Transcriptomic Analysis

130 wyświetleń

⸱

DOI:

10.3791/71735

⸱

11 sierpnia 2026

* These authors contributed equally

W tym artykule

Podsumowanie

This protocol integrates public transcriptomic datasets and colonic epithelial cell validation to identify S100P as a shared biomarker associated with inflammatory bowel disease, colorectal cancer, and pancreatic adenocarcinoma.

Streszczenie

Inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (CRC) and pancreatic adenocarcinoma (PAAD), yet the molecular features shared among these diseases remain incompletely understood. This study aimed to identify common genes and biological pathways associated with IBD, CRC, and PAAD through integrated transcriptomic analysis and experimental validation. Gene expression datasets for IBD, CRC, and PAAD were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. Weighted gene co-expression network analysis and differential expression analysis were performed to identify disease-associated and shared genes. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (analyses were used to explore enriched biological functions and pathways. Immune cell infiltration was evaluated using Cell-type Identification by Estimating Relative Subsets of RNA Transcripts. Receiver operating characteristic analysis was performed to assess the diagnostic performance of common genes. Single-cell RNA sequencing analysis was conducted to examine the cellular distribution of S100P. In addition, the effects of S100P downregulation were evaluated in lipopolysaccharide (LPS)-stimulated colonic epithelial cells. A total of 162 disease-associated genes and four common genes were identified. Functional enrichment analyses indicated significant enrichment of immune- and inflammation-related pathways, including the interleukin-17 signaling pathway. Immune infiltration analysis revealed similar trends in several immune cell populations across IBD, CRC, and PAAD. Single-cell analysis showed elevated S100P expression in epithelial cells from all three diseases. Downregulation of S100P restored the proliferative capacity of LPS-stimulated colonic epithelial cells and reduced inflammatory cytokine expression. Integrated transcriptomic analysis identified S100P as a biomarker associated with IBD, CRC, and PAAD and highlighted shared immune-related features across these diseases.

Wprowadzenie

Inflammatory bowel disease (IBD) represents a spectrum of immune-related disorders that affect the gastrointestinal tract, including ulcerative colitis and Crohn’s disease1. The etiology of IBD is highly complex, involving mucosal immune abnormalities, dysbiosis, and genetic susceptibility2. IBD is a global health concern with increasing incidence rates and substantial economic burdens, and its growing prevalence has attracted considerable attention1. Importantly, patients with IBD have a significantly increased risk of developing colorectal cancer (CRC)3 and pancreatic adenocarcinoma (PAAD)4. Although this association has been well documented, the genetic crosstalk among IBD, CRC, and PAAD remains incompletely understood.

Previous studies strongly suggest that IBD, CRC, and PAAD share common pathogenic processes; however, specific and sensitive diagnostic biomarkers remain lacking, and the shared pathogenic mechanisms have not been fully elucidated. Fortunately, with the rapid advancement and widespread availability of high-throughput sequencing technologies, numerous transcriptomic datasets from patients with IBD, CRC, and PAAD have become publicly available, enabling systematic investigation of the molecular interconnections among these diseases2,5,6.

This study employed high-throughput sequencing data from patients with IBD, CRC, and PAAD to identify disease-associated and shared genes using weighted gene co-expression network analysis (WGCNA) and differential expression analysis. These genes were further investigated to identify potential shared signaling pathways among IBD, CRC, and PAAD. Additionally, we evaluated the diagnostic value of these common genes. Single-cell RNA sequencing (scRNA-seq) analysis demonstrated that the key gene S100P was predominantly expressed in epithelial cells. Finally, we investigated the biological role of S100P in IBD.

In conclusion, this study aimed to identify common diagnostic biomarkers and biological pathways associated with IBD, CRC, and PAAD, thereby providing valuable clinical insights into the shared prevention and treatment of these diseases.

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Protokół

This study used publicly available, de-identified datasets from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), as well as established commercial cell lines. No newly recruited human participants, identifiable patient information, or patient-derived samples were involved. All analyses were performed in accordance with relevant institutional guidelines and the terms of use of the public databases. Therefore, additional institutional ethical approval and informed consent were not required for this study.

Data Source
RNA-seq data for the IBD cohorts (GSE179285; platform: GPL6480 and GSE24287; platform: GPL6480), CRC cohorts (TCGA-CRC; platform: Illumina HiSeq 2000 and GSE87211; platform: GPL13497), and PAAD cohorts (GSE128735; platform: GPL20301 and GSE62452; platform: GPL6244) were downloaded from TCGA and the GEO. All datasets were accessed on December 5, 2025.

For each dataset, samples were strictly divided into two subgroups, with disease lesion/tumor tissues serving as the case group and corresponding non-lesion normal tissues serving as the control group. Specifically, the IBD cohort contained 297 intestinal mucosal samples from patients with IBD and 56 normal intestinal mucosal samples from healthy individuals; the CRC cohort included 841 primary colorectal tumor tissues and 211 matched adjacent normal colorectal epithelial tissues; and the PAAD cohort consisted of 114 PAAD tumor tissues and 106 normal pancreatic parenchymal tissues.

All datasets within the same disease category were integrated uniformly. The limma package’s normalizeBetweenArrays function was applied to perform cross-sample quantile normalization, effectively eliminating inter-platform batch effects and standardizing gene expression values across different datasets for subsequent differential expression analysis.

Screening of IBD-, CRC-, and PAAD-Related Genes and Common Genes
First, differentially expressed genes (DEGs) were screened from the IBD, CRC, and PAAD cohorts using the limma package, and the original P values were corrected using the Benjamini-Hochberg false discovery rate (FDR) method. In the IBD, CRC, and PAAD cohorts, the screening criteria were set at |logFC| > 0.4 and P < 0.05. Additionally, WGCNA was performed on all genes, with a minimum module gene threshold of 100 (soft-threshold power = 0.90; network type = signed). Consequently, common DEGs and module genes were identified across the three cohorts. Genes consistently identified by both methods were defined as common genes, whereas the remaining genes were categorized as related genes.

PPI and Functional Enrichment Analysis
These analyses were performed on the disease-associated genes. Protein–protein interaction (PPI) analysis was conducted using the STRING database (interaction score > 0.40). Functional enrichment analysis included Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, which were performed using the clusterProfiler, enrichplot, and org.Hs.eg.db packages (P < 0.05 and FDR-adjusted q value [Benjamini–Hochberg method] < 0.05).

Immune Microenvironment Profiling
CIBERSORT is a reliable algorithm for estimating immune cell infiltration levels from gene expression data using the default LM22 signature matrix7. In this study, the CIBERSORT algorithm was used to estimate the extent of immune cell infiltration in samples from the IBD, CRC, and PAAD cohorts to explore the shared characteristics of the immune microenvironment among the three diseases. The analysis was performed with 1,000 permutations to calculate P values for each sample, and quantile normalization (QN = TRUE) was applied to the mixture expression file. Only samples with a CIBERSORT P value < 0.05 were retained for subsequent analyses, ensuring the reliability of the deconvolution results.

Assessment of the Diagnostic Value of Common Genes
The diagnostic value of the common genes in the IBD, CRC, and PAAD cohorts was evaluated using receiver operating characteristic (ROC) analysis with the pROC package in R. The optimal trade-off between sensitivity and specificity was visualized using ROC curves.

qRT-PCR, Cell Transfection, and Colony Formation Assay
qRT-PCR and cell transfection were conducted according to previous studies8,9,10. Transient transfection was performed using jetPRIME transfection reagent (Polyplus, China) according to the manufacturer's instructions. Cells were incubated with the transfection mixture for 6 h, after which the medium was replaced with complete DMEM. Subsequent experiments were performed 48 h after transfection.

Briefly, total cellular RNA was extracted using TRIzol reagent. RNA was reverse-transcribed into cDNA using PrimeScript RT Master Mix. Quantitative PCR was performed using TB Green qPCR. β-actin was used as the internal reference gene for expression normalization. Biological experiments were performed in triplicate. The primer sequences and the siS100P sequence can be found in a previous study 11.

NCM460, FHC, HCT116, SW116, PANC1, and BXPC2 cells were obtained as listed in the Table of Materials. All cell lines underwent cell identification and mycoplasma testing.

During the experiments, all cells were passaged for 3–5 generations. All cells were cultured in complete DMEM containing 10% fetal bovine serum and 1% penicillin–streptomycin.

The colony formation assay was performed as described in a previous study12. Briefly, 1,000 cells were seeded into each well of a 6-well plate and cultured for 10 days before the experiment was terminated. Cells were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and colonies were counted using ImageJ.

Analysis of Common Genes Based on scRNA-seq Data
scRNA-seq data from the IBD dataset (GSE214695), CRC dataset (GSE166555), and PAAD dataset (GSE154778) were preprocessed as described in previous studies8,13. Raw count matrices were collapsed by mean expression for duplicate gene symbols using limma::avereps. Initial filtering retained genes detected in at least three cells and cells containing at least 50 unique transcripts. Cells with a mitochondrial transcript fraction >5% or fewer than 50 detected genes were removed. Log normalization was performed with a scale factor of 10,000, followed by variance-stabilizing transformation to identify the top 1,500 highly variable genes, which were Z-score standardized prior to principal component analysis (PCA). Cluster-defining marker genes were filtered using log2(fold change) > 0.5, a detection fraction ≥0.25 in target clusters, and an adjusted P value <0.05.

Briefly, data preprocessing was conducted using the Seurat package, and cell type annotation was performed using the SingleR package (version 2.6.0). Cell clustering was performed in Seurat using k-nearest neighbor graph construction and t-SNE embedding based on PCA dimensions 1–20. The distribution and expression levels of the common genes across different cell types were then examined.

Construction of the IBD Model
According to previous studies14, lipopolysaccharide (LPS) was used to induce inflammation in normal human colonic epithelial cells (FHC and NCM460), thereby generating an inflammation-mimicking IBD model. Biological experiments were performed in triplicate. Cells were routinely cultured in a humidified incubator at 37°C with 5% CO2. When cell confluence reached approximately 50%–70%, the culture medium was replaced with fresh complete medium, and the cells were treated with 10 ng/mL LPS for 12 h. An equal volume of sterile phosphate-buffered saline (PBS) was used as the vehicle control. The culture volume was 2 mL per well in 6-well plates. After treatment, the medium was removed, the cells were washed twice with pre-cooled sterile PBS, and the cells were collected for subsequent analyses.

Statistical Analysis
All bioinformatics analyses were performed using R software (version 4.1.2). Comparisons between two groups were performed using Student's t-test, whereas comparisons among multiple groups were performed using one-way analysis of variance (ANOVA). Correlation analysis was performed using the Spearman method. All cellular experiments were repeated at least three times, and the data are presented as the mean ± standard deviation (SD). A P value or FDR < 0.05 was considered statistically significant. NS, not significant; P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***).

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Wyniki

DEG w IBD, CRC i PAAD
W pierwszej kolejności zintegrowano kohorty IBD (GSE179285 i GSE24287), kohorty CRC (TCGA-CRC i GSE87211) oraz kohorty PAAD (GSE128735 i GSE62452), a następnie oceniono proces integracji za pomocą PCA oraz wykresów gęstości ekspresji genów. Wyniki wykazały, że efekty serii między różnymi zbiorami danych zostały skutecznie wyeliminowane po integracji (Rysunek 1A–F).

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Dyskusja

Previous studies have highlighted the association of IBD, an immune-related gastrointestinal disorder, with several diseases, including neurodegenerative diseases17, multiple sclerosis18, amyotrophic lateral sclerosis19, endometriosis20, rheumatoid arthritis2, Hodgkin’s lymphoma21, CRC22, and PAAD23. IBD is generally considere...

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Oświadczenia

Conflict of Interest:
The authors declare no competing interests.

Podziękowania

The authors acknowledge financial support from the National Key R&D Plan of China (Grant No. 2023YFB3210400).

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Materiały

Lista materiałów użytych w tym artykule
NazwaFirmaNumer katalogowyKomentarze
BXPC2 cell lineCell Bank of the Chinese Academy of SciencesN/AHuman pancreatic adenocarcinoma cell line
CIBERSORTN/AN/AImmune cell infiltration analysis
clusterProfiler packageBioconductorv4.8.0Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses
Dulbecco's Modified Eagle Medium (DMEM)Thermo Fisher Scientific11965092Cell culture medium
Fetal bovine serum (FBS)Thermo Fisher ScientificA5256701Cell culture supplement
FHC cell lineCell Bank of the Chinese Academy of SciencesN/AHuman normal colonic epithelial cell line
GEO dataset (GSE128735)Gene Expression Omnibus (GEO)N/APublic gene expression dataset for pancreatic adenocarcinoma
GEO dataset (GSE154778)Gene Expression Omnibus (GEO)N/APublic single-cell RNA sequencing dataset for pancreatic adenocarcinoma
GEO dataset (GSE166555)Gene Expression Omnibus (GEO)N/APublic single-cell RNA sequencing dataset for colorectal cancer
GEO dataset (GSE179285)Gene Expression Omnibus (GEO)N/APublic gene expression dataset for inflammatory bowel disease
GEO dataset (GSE214695)Gene Expression Omnibus (GEO)N/APublic single-cell RNA sequencing dataset for inflammatory bowel disease
GEO dataset (GSE24287)Gene Expression Omnibus (GEO)N/APublic gene expression dataset for inflammatory bowel disease
GEO dataset (GSE62452)Gene Expression Omnibus (GEO)N/APublic gene expression dataset for pancreatic adenocarcinoma
GEO dataset (GSE87211)Gene Expression Omnibus (GEO)N/APublic gene expression dataset for colorectal cancer
ggplot2 packageCRANv3.4.2Data visualization
HCT116 cell lineCell Bank of the Chinese Academy of SciencesN/AHuman colorectal cancer cell line
ImageJNational Institutes of Health (NIH)v1.8.0Colony counting
jetPRIME Transfection ReagentPolyplus101000046Cell transfection
Lipopolysaccharide (LPS)Beyotime Co., LtdS1735Induction of an inflammation-mimicking IBD cell model
limma packageBioconductorv3.54.0Differential expression analysis
NCM460 cell lineCell Bank of the Chinese Academy of SciencesN/AHuman normal colonic epithelial cell line
org.Hs.eg.db packageBioconductorv3.23.1Gene annotation for enrichment analysis
PANC1 cell lineCell Bank of the Chinese Academy of SciencesN/AHuman pancreatic adenocarcinoma cell line
Penicillin–streptomycinThermo Fisher Scientific15140-122Antibiotic supplement for cell culture
pheatmap packageCRANv1.0.12Heatmap visualization
pROC packageCRANv1.19.0.1Receiver operating characteristic (ROC) analysis
PrimeScript RT Master MixTakara BioRR036AReverse transcription of RNA into cDNA
Primer sets for qRT-PCRTsingke Biotech Co., LtdN/APrimer sequences reported in Reference 11
R softwareR Foundation for Statistical Computingv4.1.2Statistical and bioinformatics analyses
Seurat packageCRANv4.0Single-cell RNA sequencing data preprocessing and analysis
siS100PTsingke Biotech Co., LtdN/ASmall interfering RNA targeting S100P
SingleR packageBioconductorv2.6.0Cell type annotation for single-cell RNA sequencing
STRING databaseSTRING ConsortiumN/AProtein-protein interaction analysis
SW1116 cell lineCell Bank of the Chinese Academy of SciencesN/AHuman colorectal cancer cell line
TB Green qPCR MixTakara BioRR430BQuantitative real-time PCR
TCGA-CRC datasetThe Cancer Genome Atlas (TCGA)N/APublic colorectal cancer transcriptomic dataset
TRIzol reagentInvitrogen15596-026Total RNA extraction
WGCNA packageCRANv1.73Weighted gene co-expression network analysis

Bibliografia

  1. Xu R, Du W, Yang Q, Du A. ITGB2 related to immune cell infiltration as a potential therapeutic target of inflammatory bowel disease using bioinformatics and functional research. Journal of cellular and molecular medicine. 2024;28(15):e18501.
  2. Sun HW, Zhang X, Shen CC. The shared circulating diagnostic biomarkers and molecular mechanisms of systemic lupus erythematosus and inflammatory bowel disease. Frontiers in immunology. 2024;15:1354348.
  3. Faye AS, Holmer AK, Axelrad JE. Cancer in inflammatory bowel disease. Gastroenterology clinics of North America. 2022;51(3):649-66.
  4. Yu J, et al. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study. United European gastroenterology journal. 2022;10(2):212-24.
  5. Xia B, et al. Identification of potential shared gene signatures between gastric cancer and type 2 diabetes: A data-driven analysis. Frontiers in medicine. 2024;11:1382004.
  6. Luo Y, et al. Exploring the molecular mechanism of comorbidity of type 2 diabetes mellitus and colorectal cancer: Insights from bulk omics and single-cell sequencing validation. Biomolecules. 2024;14(6).
  7. Newman AM, et al. Robust enumeration of cell subsets from tissue expression profiles. Nature methods. 2015;12(5):453-7.
  8. Sun W, et al. Construction and validation of a novel senescence-related risk score can help predict the prognosis and tumor microenvironment of gastric cancer patients and determine that STK40 can affect the ROS accumulation and proliferation ability of gastric cancer cells. Frontiers in immunology. 2023;14:1259231.
  9. Hong J, et al. A zinc metabolism-related gene signature for predicting prognosis and characteristics of breast cancer. Front Immunol. 2023;14:1276280.
  10. Man KF, et al. CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance. Oncogene. 2025;44(16):1093-105.
  11. Zhou H, et al. S100P promotes trophoblast syncytialization during early placenta development by regulating YAP1. Frontiers in endocrinology. 2022;13:860261.
  12. Zhou C, et al. Novel exosome-associated LncRNA model predicts colorectal cancer prognosis and drug response. Hereditas. 2025;162(1):79.
  13. Hong J, et al. Integrative PANoptosis-focused omics analysis uncovers GSDMC as a candidate biomarker in breast cancer. Frontiers in Cell and Developmental Biology. 2026;Volume 14 - 2026.
  14. Qiu C, et al. Hsa_circ_0004662 accelerates the progression of ulcerative colitis via the microRNA-532/HMGB3 signalling axis. Journal of cellular and molecular medicine. 2025;29(6):e70430.
  15. Schmid F, et al. Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker. British journal of cancer. 2022;127(4):675-85.
  16. Arumugam T, Simeone DM, Van Golen K, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11(15):5356-64.
  17. Zong J, et al. The two-directional prospective association between inflammatory bowel disease and neurodegenerative disorders: A systematic review and meta-analysis based on longitudinal studies. Frontiers in immunology. 2024;15:1325908.
  18. Yaqubi K, et al. Inflammatory bowel disease is associated with an increase in the incidence of multiple sclerosis: A retrospective cohort study of 24,934 patients. European journal of medical research. 2024;29(1):186.
  19. Li CY, et al. Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases. BMC medicine. 2021;19(1):27.
  20. Shigesi N, et al. The association between endometriosis and autoimmune diseases: A systematic review and meta-analysis. Human reproduction update. 2019;25(4):486-503.
  21. Sonnenberg A, Duong HT, McCarty DJ, El-Serag HB. Concurrence of inflammatory bowel disease with multiple sclerosis or Hodgkin lymphoma. European journal of gastroenterology & hepatology. 2023;35(12):1349-53.
  22. Chacon-Millan P, et al. A combination of microarray-based profiling and biocomputational analysis identified miR331-3p and hsa-let-7d-5p as potential biomarkers of ulcerative colitis progression to colorectal cancer. International journal of molecular sciences. 2024;25(11).
  23. Everhov Å H, et al. Inflammatory bowel disease and pancreatic cancer: A Scandinavian register-based cohort study 1969-2017. Alimentary pharmacology & therapeutics. 2020;52(1):143-54.
  24. Contran N, et al. Colorectal cancer and inflammatory bowel diseases share common salivary proteomic pathways. Scientific reports. 2024;14(1):17711.
  25. Sun W, et al. Osthole pretreatment alleviates TNBS-induced colitis in mice via both cAMP/PKA-dependent and independent pathways. Acta pharmacologica Sinica. 2017;38(8):1120-8.
  26. Li SY, et al. Diosgenin exerts anti-tumor effects through inactivation of cAMP/PKA/CREB signaling pathway in colorectal cancer. European journal of pharmacology. 2021;908:174370.
  27. Castro-Pando S, et al. Pancreatic epithelial IL17/IL17RA signaling drives B7-H4 expression to promote tumorigenesis. Cancer immunology research. 2024;12(9):1170-83.
  28. Kayed H, et al. FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. International journal of cancer. 2006;118(1):43-54.
  29. Wang H, et al. Mesenchymal stem cells ameliorate DSS-induced experimental colitis by modulating the gut microbiota and MUC-1 pathway. Journal of inflammation research. 2023;16:2023-39.
  30. Li W, et al. MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI insight. 2020;5(12).
  31. Murthy D, et al. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Proceedings of the National Academy of Sciences of the United States of America. 2024;121(14):e2315509121.
  32. Sun W, et al. TRIM47 regulates energy metabolism via glycolytic reprogramming to drive hepatocellular carcinoma progression and represents an efficient therapeutic target. Adv Sci (Weinh). 2026;13(17):e16996.
  33. Sun W, et al. METTL4 enhances GLI1 translation through m(6)Am modification to promote tumor progression as a therapeutic target for hepatocellular carcinoma. J Adv Res. 2026.
  34. Yuan Y, et al. RNA nanotherapeutics for hepatocellular carcinoma treatment. Theranostics. 2025;15(3):965-92.

Dostęp ograniczony. Zaloguj się lub rozpocznij wersję próbną, aby wyświetlić tę treść.

Przedruki i uprawnienia

Tagi

Badania nad rakiemnumer 234numer 234nieswoiste zapalenia jelitrak jelita grubegogruczolakorak trzustkidiagnostykaodpornościowyS100P